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Abstract
Introduction: Deposition of amyloid fibrils derived from circulating acute-phase reactant serum amyloid A protein 
causes systemic amyloidosis, a serious inflammatory disorder. We document a male patient who developed reactive 
amyloidosis (AA type), most likely secondary to his long standing periodontitis.
Case presentation: A 67-year-old Turkish man complained of pain in his oral cavity (burning mouth) especially on the 
tongue, and had difficulty chewing and swallowing foods. A careful dental/periodontal examination was performed, 
including assessment of plaque, gingival condition and periodontal probing depths on all his remaining teeth. 
Prosthetic rehabilitation was provided three months after the completion of his periodontal and surgical therapy. The 
concentration of serum inflammatory markers including erythrocyte sedimentation rate, white blood cell count, 
fibrinogen and high sensitive C-reactive protein were measured at baseline, at the second and sixth weeks, and at 
three and six months after the periodontal and surgical therapy.
Conclusions: Oral examination revealed a few papules on the dorsum of the tongue with two slightly painful, small 
ulcers, localized on the vestibule of the mouth. The mean probing depth was 9.10 ± 0.84 mm. Biopsies of the tongue, 
buccal mucosa and retromolar trigone were performed and amyloid deposits were found. The serum inflammatory 
markers improved more dramatically at the second week of periodontal therapy than any other time intervals.
Amyloidosis may manifest as periodontal destruction that leads to severe chronic periodontitis. Proper periodontal 
treatment may alleviate systemic inflammatory mediators caused by the amyloidosis.
Introduction
Reactive systemic AA amyloidosis, with a sustained acute
phase response (APR), can complicate chronic inflamma-
tory disorders. AA amyloid fibrils are derived from the
acute-phase reactant serum amyloid A protein (SAA)
through a process of cleavage, misholding, and aggrega-
tion [1]. Renal disease is a frequent manifestation of the
systemic amyloidosis and a major cause of morbidity [1].
SAA is an apolipoprotein constituent of high-density
lipoprotein that is synthesized by hepatocytes under the
transcriptional regulation of pro-inflammatory cytokins
[2]. Sustained overproduction of SAA is a prerequisite for
the development of AA amyloidosis. Amyloidosis affects
a small proportion of patients that present with chronic
inflammatory disorders [3,4]. The etiologies for this dis-
ease remain unknown. The activation pattern of SAA
protein in the presence of inflammation is similar to that
of C-reactive protein (CRP) [5]. The level of SAA
increases during acute and chronic infections [6,7]. It has
been shown that patients with chronic periodontitis dis-
play signs of a sub-clinical systemic inflammatory condi-
tion [8]. Furthermore, treatment of advanced
periodontitis by full-mouth tooth extraction reduced sys-
temic levels of cardiovascular risk and inflammatory
reaction [9].
Cross-sectional studies have demonstrated that plasma
levels of inflammatory markers such as CRP, fibrinogen,
IL-6 and leukocyte counts increase in periodontitis
patients when compared to periodontally healthy patients
[9,10]. Some studies have shown that effective periodon-
tal therapy reduced levels of CRP [11]. This implies that
inflammatory reaction triggered by periodontitis contrib-
utes to the whole-body inflammatory burden.
Secondary amyloidosis, representing approximately
45% of all cases of systemic amyloidosis, has been associ-
ated with various chronic inflammatory conditions such
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Page 2 of 6as rheumatoid arthritis, sarcoidosis, Crohn's disease,
ulcerative colitis and tuberculosis [12]. Secondary amy-
loidosis has also been linked to malignant diseases such
as Hodgkin's disease and mesothelioma [12]. In addition,
familial Mediterranean fever (FMF), an autosomal reces-
sive disease, primarily affects the population in the Medi-
terranean basin [13]. FMF is characterized by recurrent
episodes of fever and serosal inflammation along with a
very intense APR. The most important complication of
FMF is secondary amyloidosis [13]. Mutation analysis of
Mediterranean fever gene (MEFV) can be helpful in con-
firming the diagnosis for patients with an atypical presen-
tation. Infection or inflammatory diseases may cause AA
amyloidosis even without obvious infection or inflamma-
tion [14,15]. The progression of secondary amyloidosis
depends on the nature and status of the underlying
chronic inflammatory disease. For example, secondary
amyloidosis-associated tuberculosis has been shown to
undergo remission when the chronic infection has been
eliminated [16].
Histopathologic examination of amyloid is essential for
the diagnosis and classification of amyloidosis [17,18].
The sensitivity and specificity of the histopathologic diag-
nosis depend on the biopsy site and the adequacy of the
tissue sample [19,20].
Case presentation
Our patient is 67-year-old Turkish man, a primary school
graduate, and a forest ranger who lives in a rustic area. He
was fully informed about the study and written consent
was obtained from him prior to examination. In his med-
ical examination he explained that his gums started
bleeding at a very early age. At age 24, he started to smoke
since he thought smoking would help to stop bleeding.
Currently, he smokes 1-1.5 packs a day. At age 30, he
started to experience difficulty in eating and complained
of tooth mobility and gum bleeding. He claimed that his
teeth ached a lot and as a result the teeth were extracted
by a non-dentist or himself. Consequently, at the age of
50 to 60, he lost most of his teeth. At age 25, he was diag-
nosed with periodontitis. Nonetheless, he had not seen a
dentist for this problem or performed any personal oral
hygiene.
Our patient complained of pain in the oral cavity espe-
cially on the tongue, buccal mucosa and had difficulty in
chewing and swallowing solid food for six months.
His past medical history was significant for a tonsillec-
tomy as a child. All the symptoms in his medical reviews
were negative. Spirometric pulmonary tests were normal.
High resolution computed tomography (HRCT) showed
minimal emphysematous areas over both apices and non-
specific sequelae (Figure 1). Head and neck examinations
were normal. Magnetic resonance imaging of the tongue
revealed no sign of abnormality. He underwent extensive
tests to identify the etiologies associated with systemic
amyloidosis. Tests such as rectal biopsy, bone marrow
biopsy, echocardiogram, abdomen tomography, serum
and urine protein electrophoresis as well as liver function
test were all normal. However, our patient was diagnosed
as chronic renal failure with proteinuria and hypoalbu-
minemia (Table 1). Renal biopsy showed AA type amyloi-
dosis.
Clinical examination revealed poor oral hygiene and
heavy plaque accumulation. Our patient was almost com-
pletely edentulous. The mean periodontal probing depth
was 9.10 ± 0.84 mm (range 8-10 mm) in his remaining
teeth. The tongue was diffusely enlarged (macroglossia)
and clear red appearance and bilateral white plaques
bleeding easily by gentle removing, and irregular translu-
cent papules were present (Figure 2). Based upon our
patient's history, these papules developed spontaneously
or after minor trauma. The enlarged tongue has inter-
fered with speech and swallowing, and caused sleep
apnea. In addition, two painful, small flat-based ulcers
with erythematous halos and a white ulcer bed were
detected, localized on the right and left buccal mucosa.
Cultures from the plaques on the tongue and oral cavity
were all negative for bacteria and fungi. The biopsies were
obtained from the tongue, buccal mucosa and retromolar
trigon. Secondary amyloidosis (AA type), was diagnosed
Figure 1 High resolution computed tomography (HRCT) showed 
minimal emphysematous areas over both apices and non-specif-
ic sequalae.
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ure 3).
Our patient received comprehensive periodontal ther-
apy, which included careful oral hygiene instructions,
curettage combined with non-surgical and surgical ther-
apy. Serum inflammatory markers and some laboratory
data improved dramatically at the second week of the
periodontal therapy more than at any other time interval
(Table 1). Restorative treatment started after his peri-
odontal condition was stabilized (around three months
after periodontal therapy). Intra-oral radiographs showed
poor bone density (Figure 4).
Histopathologic examination findings
The Congo red method was used to detect amyloid in tis-
sue sections [21]. Amyloid was identified as the AA type
on immunohistochemical tests with the use of monoclo-
nal antibodies specific to amyloid A [18].
Discussion
Our patient was 67-year-old man, a heavy and current
smoker. He suffered severe chronic periodontitis and
chronic renal failure. Our patient complained of pain in
the oral cavity especially on the tongue, buccal mucosa
and had difficulty in chewing and swallowing solid foods
Table 1: The effect of periodontal therapy on the inflammatory markers and some laboratory data
Parameters Before treatment After treatment
Second week Third week Third month Sixth month
ESR (mm/h) 107 64 60 54 50
WBC (× 103 ml) 18 10.09 9.4 8.5 8.4
Fibrinogen (mg/dl) 374.95 280 240 235 236
hs-CRP(mg/l) 58 34 30 28 28
Serum Albumin (g/dl) 1.8 1.9 2 2.1 2.4
Serum creatinine (mg/dl) 3.5 3 3 3 3
Proteinuria (g/day) 2.4 1.5 1.5 1.5 1.5
RF Negative
MEFV Negative
FCV 3.14 (82.4%)
FEV1 2.67 (105.7%)
FEF/FCV 85%
FEF 2575:2.88(90.6%)
HRCT Minimal emphysematous areas
ESR: erythrocyte sedimentation rate (< 10 mm/hour); WBC: white blood cell; Fibrinogen; Serum albumin; hs-CRP: high sensitive C-reactive protein 
(< 3 mg/L); RF: rheumatoid factor; MEFV: Mediterranean fever gene mutation; FVC: forced vital capacity; FEV1: forced expiratory volume in a 
second; FEF 25-75: forced expiratory flow 25%-75%; HRCT: high resolution computed tomography
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ondary amyloidosis was diagnosed based upon histologi-
cal and immunohistochemical findings. Our patient
presented with typical signs of periodontal disease that
include gingival tenderness, bleeding, recession, alveolar
bone loss, tooth mobility, and tooth loss. In addition, sev-
eral inflammation markers, such as erythrocyte sedimen-
tation rate (ESR), white blood cell count (WBC),
fibrinogen and high sensitive C-reactive protein (hs-CRP)
were all elevated.
It has been shown that chronic infection or inflamma-
tory diseases may cause secondary amyloidosis even
without obvious infection or inflammation [14,15].
Patients with chronic periodontal diseases had higher
levels of SAA, the precursor protein of amyloid fiber in
secondary amyloidosis, than patients without periodontal
disease [22]. To date, only a few reports address the inter-
action between periodontal disease and secondary amy-
loidosis [20,23]. One study showed the prevalence of
moderate to severe periodontitis was greater in FMF
patients with amyloidosis than without amyloidosis [20].
The other study was a case report that illustrated an
interaction between systemic amyloidosis and severe
periodontitis in a patient with rheumatoid arthritis [23].
Our case results were in line with findings reported in the
literature.
The definitive method of diagnosing amyloidosis is tis-
sue biopsy. Although biopsies can be obtained from com-
promised organs, blood vessel fragility associated with
amyloid deposition carries a risk of bleeding. Biopsy of
oral tissues has been advocated as an adjunctive or alter-
nate method of detecting amyloid deposition. Gingival,
tongue, buccal mucosa and minor salivary gland tissue
Figure 2 The tongue was diffusely enlarged (macroglossia), and 
bilateral white plaques and irregular translucent papules are 
seen.
Figure 3 Histopathologic examination findings: the Congo red 
method was used to detect amyloid in tissue sections. Amyloid 
was identified as the AA type on immunohistochemical testing with 
the use of monoclonal antibodies specific to SAA. (A) Hematoxylin and 
eosin staining of the biopsy specimen shows homogen, eosinophilic 
material (×20, hemotoxylin and eosin). (B) The amorphous extra-cellu-
lar material stains positively with Congo red (×2.5, Congo red). (C) This 
Congo red-positive material appears apple-green when viewed under 
polarized light (×20 Congo red-positive material appears apple-green 
when viewed under polarized light). (D) Extra-cellular and peri-vascular 
deposits of amyloid reveal positive immunoreactivity with an antibody 
against amyloid A (×40).
A B
C D
Figure 4 Radiographic findings from the patient described in this 
case report. Diffuse osteopeny in mandibular and prominence trabe-
culation of maxilla are present.
Cengiz et al. Journal of Medical Case Reports 2010, 4:200
http://www.jmedicalcasereports.com/content/4/1/200
Page 5 of 6have all been reported as potential sites for biopsy; how-
ever, there are inconsistent results with regard to the sen-
sitivity of amyloid detection in each of these tissues [24].
As a result, it has been reported that the anatomic loca-
tion of the amyloid deposition within the tissue was con-
sistent regardless of the location of the biopsy. This may
have important implications for the biopsy technique
used for the detection of amyloid [24]. If intra-oral biop-
sies are used more commonly for patients with chronic
periodontal disease, amyloid may be found more fre-
quently than expected.
Our patient's differential diagnosis include pulmonary
X-ray, pulmonary function tests, sputum cytology, fasting
gastric juice and tuberculin skin testing, they were all
negative for tuberculosis and bronchiectasis. His history,
physical examination and laboratory findings were nega-
tive for rheumatoid arthritis and FMF patients (rheuma-
toid factor and MEFV gene mutation were negative,
respectively). There was no evidence for chronic infec-
tion or inflammation such as rheumatoid arthritis, sarcoi-
dosis, Crohn's disease, ulcerative colitis and tuberculosis
except chronic periodontitis. In addition, smoking is a
strong risk factor for periodontitis [25] and it certainly
contributed to our patient's problems since he is a heavy
smoker (more than 1-1.5 packs/day).
Secondary amyloidosis is also associated with malig-
nant diseases such as Hodgkin's disease and mesothe-
lioma. Clinical examination, abdominal and chest
computed tomography were negative for any malignant
disorders or airflow obstruction. With the decline of
tuberculosis in the developed countries, rheumatoid
arthritis and inflammatory bowel disease remain the
leading cause of secondary amyloidosis [12]. However, in
the developing countries, chronic infectious diseases
such as tuberculosis and leprosy are major causes [12].
There was no clinical evidence for inflammatory bowel
diseases or leprosy in our patient.
Although, our patient did not have any pulmonary sys-
tem complaints, due to his habit of smoking, his pulmo-
nary system was investigated extensively for disease that
might trigger the secondary amyloidosis. All pulmonary
function tests were normal except a mild emphysematous
appearance on chest computed tomography. No bron-
chiectasis or obstruction was noted. So far, no secondary
amyloidosis or increased inflammatory markers in
patients with mild or moderate emphysema has been
reported [26].
A thorough investigation for the etiology that may
cause secondary amyloidosis was carried out. None was
identified except chronic periodontitis. Our patient
developed reactive amyloidosis (AA-type), most likely
secondary to his long-standing periodontitis. This could
be attributed to the increase in the levels of systemic
inflammatory mediators due to chronic periodontal dis-
ease/infection that led to the secondary amyloidosis.
Indeed, patients with chronic periodontal diseases have
higher levels of SAA protein in secondary amyloidosis
than patients without periodontal disease [22]. Chronic
periodontal disease could exaggerate secondary amyloi-
dosis via increased levels of systemic inflammatory medi-
ators. In addition, our report highlights the possibility
that amyloid deposition in patients with systemic amyloi-
dosis causes accelerated periodontal destruction and
bone loss of affected teeth. Amyloid deposition within the
periodontium elicited an inflammatory reaction similar
to that of foreign body material. Accelerated destruction
of periodontium and associated supporting bone appar-
ently is caused by this foreign-body-type giant cell reac-
tion. Therefore, elimination of local infection associated
with periodontal diseases will aid in the reduction of lev-
els of systemic inflammatory mediators, which may slow
the progression of secondary amyloidosis.
Sustained overproduction of SAA is a prerequisite for
the development of AA amyloidosis, although the reasons
for these remain unknown. Robbins [27] proposed two
possible explanations for this. First, SAA-protein is nor-
mally degraded to soluble end products via monocyte-
derived enzymes. Conceivably, individuals who develop
amyloid have an enzyme defect that cannot breakdown
SAA-protein completely hence insoluble AA molecules
were produced. Second, a genetically determined struc-
tural abnormality in the SAA-protein molecule itself ren-
ders it resistant to degradation by monocytes. Evidence
has suggested that individual genetic susceptibility to
amyloidosis may influence the host's response to infec-
tion. Nibali et al. [28] have found the link between poly-
morphisms of genes encoding for neutrofil receptors and
pro-inflammatory cytokines and the presence of patho-
genic bacteria in patients with aggressive periodontits.
The authors then speculated that complex interactions
between the microbiota and host genome may be at the
basis of a patient's susceptibility to aggressive periodonti-
tis. Currently many investigators are trying to define the
genotype-phenotype correlations and risk factors for the
development of secondary amyloidosis.
Conclusions
To our knowledge, this is the first case report that docu-
ments secondary amyloidosis supported by the tongue,
buccal mucosa and retromolar trigon biopsies, while rul-
ing out all possible known etiologic factors as a cause for
secondary amyloidosis. In addition, this study has dem-
onstrated that secondary amyloidosis can be slowed
down if periodontal condition can be improved. Further
studies in a larger population will provide insight of this
rare but destructive systemic disease.
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